In this study, we addressed the hypothesis that transcriptional suppression of erythroblastosis virus E26 oncogene homolog 1 (ETS-1) is an efficient therapeutic approach to pancreatic adenocarcinoma by investigating the effect of ETS-1 suppression in human pancreatic cancer cells. We accomplished this by using an adenoviral vector encoding only the DNA-binding domain of wild-type ETS-1 (ETS-1 dominant negative, ETS-1-DN). ETS-1-DN decreases ETS-1-binding by competing for its binding to DNA. Adenoviralmediated transfer of ETS-1-DN (adenoviral ETS-1-DN construct, AdETS-1-DN) into pancreatic tumor cell lines did not affect their proliferation rate in vitro but did significantly inhibit their in vivo growth in nude mice. Furthermore, to test the efficacy of ETS-1-DN in vivo, we injected the AdETS-1-DN into established human pancreatic adenocarcinomas grown in nude mice. This treatment significantly reduced tumor size as compared to saline injection, without any detectable side effects. Microvessel density in mouse xenografts displayed significantly lower values in tumors in which ETS-1 was downregulated. In addition, expression of the ETS-1-DN in the pancreatic cancer cells resulted in downregulation of urokinase-type plasminogen activator (u-PA) and metalloproteinase-1 (MMP-1) expression. Taken together, these data suggest that transcriptional inactivation of ETS-1 is able to significantly affect angiogenesis and growth of pancreatic cancer. This effect may be due in part to downregulation of MMP-1 and u-PA expression. Our results suggest that ETS-1-DN is a promising candidate for antiangiogenic gene therapy in pancreatic cancer.
Introduction
Although pancreatic ductal adenocarcinoma constitutes less than 2% of new cancer cases in the United States, it is the fifth leading cause of cancer-related deaths. 1 Considered by many to be one of the deadliest cancers, it is among the most studied malignancies and associated with a mean worldwide survival rate below 5%.
1,2 Although significant progress has been achieved with standard therapeutic approaches such as surgery, chemotherapy, or radiation, these approaches do not significantly improve the overall survival rate. 3 New vessel formation (angiogenesis) is a critical step in cancer progression. Clinical data have demonstrated that anti-vascular endothelial growth factor (VEGF) therapy with bevacizumab (an anti-VEGF specific antibody) is efficacious when combined with chemotherapy in colorectal and lung cancer. 4, 5 Therefore, antiangiogenesis-based approaches aimed at preventing tumor vessel growth should be introduced to improve survival rates. 6 However, a recent randomized phase 3 clinical study showed no benefit from bevacizumab in patients with pancreatic cancer. Thus, new antiangiogenic approaches are needed to treat this disease.
Controlled destruction of the principal barriers to tumor development and spread, that is, the basement membrane and extracellular matrix (ECM) compartments, is mostly influenced by the proteolytic activity surrounding a tumor mass. Although many factors regulate malignant tumor growth and spread, it is the protein profile within and interactions formed between a tumor and its microenvironment that are important for each step of tumor progression. The matrix metalloproteinases (MMPs) have recently been implicated in primary and metastatic tumor growth and angiogenesis; they also be involved in tumor promotion. 7 The MMP genes are transcriptionally responsive to a wide variety of oncogenes, growth factors, cytokines and hormones. 8 Notably, several recent studies have highlighted the erythroblastosis virus E26 oncogene homolog 1 (ETS-1) protein, which interacts with the urokinase-type plasminogen activator (u-PA) gene enhancer and with the promoters of the stromelysin-1 and MMP genes. The proto-oncogene ETS-1 is the cellular progenitor of v-ETS, a viral oncogene found in the genome of the E26 acute leukemia retrovirus. 9, 10 ETS-1 is the original member of a growing family of transcription factors that now includes over 50 members, each characterized by a conserved DNA-binding domain (EBD). The EBD binds to a consensus DNA sequence centered on a core GGAA/T motif, which has been designated as the ETS-binding site. 11 The genes for several proteins, including u-PA, MMP-1, MMP-3, MMP-9, integrin b-3, and VE-cadherin, have been reported to be downstream targets of ETS-1 in endothelial cell. 12, 13 In addition to their importance in normal cellular function, 14 ETS products have also been implicated in several malignant and genetic disorders, based on their particular target genes. It has been reported that ETS-1 activity is correlated with the tumorigenic progression of carcinoma cells of the stomach, 15 thyroid, 16 and pancreas. 17 These findings have focused our attention on the potential role of ETS-1 as a multifunctional target for antiangiogenic gene therapy. Several studies have used EBD to downregulate ETS-1 activity in capillary endothelial cells or glioma cells. ETS-1 positively regulates angiogenesis, and the elimination of ETS-1 activity by a dominant-negative molecule inhibits angiogenesis in vivo. 18, 19 Using a similar assay, downregulation of ETS-1 interfered with the expression of integrin a5, which is known to accelerate invasive events such as migration and adhesion in glioma cells. 20 Our hypothesis in undertaking this study was that transcriptional suppression of ETS-1 is an efficient therapeutic approach for pancreatic adenocarcinoma.
In the present study, we have examined the role of ETS-1 downregulation using a gene therapy approach in an animal model in which transductions were carried out either ex vivo or in vivo. We report here the data demonstrating the efficacy of this approach for blocking angiogenesis, and we concomitantly gained insights into the mechanisms involved. These results suggest that targeting ETS-1 may be a valid approach for treating pancreatic cancer.
Materials and methods

Cell lines
The pancreatic cancer cell lines used were: BxPC3, Panc-1 (American Type Culture Collection, Rockville, MD) and PCI-35 (kindly provided by Dr Hiroshi Ishikura at Hokkaido University). These lines were cultured according to the protocol provided by the suppliers. All cell lines are well characterized in terms of mutational status, as described in a previous report from our group. 21 A normal pancreatic ductal cell line HPDEC-6, a kind gift from Dr MS Tsao, University of Toronto, was propagated as originally described. 22 All cells were routinely monitored for Mycoplasma contamination as well as for mouse hepatitis, Sendai, and pneumonia viruses, and the results were consistently negative.
Adenoviral-mediated gene transfer experiments
Suppression of the ETS-1-binding activity was performed using an adenoviral vector encoding only the His-6-tagged EBD (ETS-1-binding domain) but lacking the transactivation domain and most of the automodulation module (adenoviral ETS-1-DN construct, AdETS-1-DN). The adenoviral constructs and transfection conditions have been described previously. 19, 23 Briefly, adenovirus vector encoding dominant-negative Ets-1 was constructed by homologous recombination in 293 cells between the transfer cassette bearing the expression unit of dominantnegative Ets-1 and almost the entire adenovirus genome and restriction enzyme-digested adenovirus genome tagged with terminal protein. 19 The adenovirus was applied at a concentration of 1 Â 108 plaque-forming units (PFU)/ml, and adenovirus with the genome carrying an enhanced green fluorescent protein (GFP) gene (Clontech, Palo Alto, CA) or lacZ were used as controls as described. 19 Infection efficiency was monitored by fluorescence, which showed expression in 80% of cells. Expression of recombinant protein was confirmed by western blot analysis. Conversely, to overexpress ETS-1, we used a similar vector (adenoviral ETS-1, AdETS-1) that encodes a full-length, His6-tagged ETS-1 protein. 19 Gene transfer in tumor cells was carried out using adenoviral vectors at varying multiplicity of infections (MOI) from 10 to 100 for 36 h. The LacZ gene transfer (AdLacZ) efficiency was assessed using b-galactosidase staining as described elsewhere. 24 We used the following nomenclature for the infected cells: BxPC3/ETS-1, BxPC3/ETS-1-DN, BxPC3/LacZ, PCI-35/ETS-1, PCI-35/ETS-1-DN, PCI-35/LacZ, Panc-1/ETS-1, Panc-1/ ETS-1-DN, and Panc-1/LacZ. His6-tagged ETS-1 was detected by immunocytochemistry using an anti-His6 antibody (Sigma Chemical Co., St Louis, MO), according to the provider's protocol.
RT-PCR
Reverse transcription (RT)-PCR was performed using methods described previously. 25, 26 Expression of the hMSH2 gene was monitored as a positive control as the gene was demonstrated to be expressed in all parental cells. 27 Samples of 29 primary human pancreatic cancers as well as the corresponding normal pancreatic tissues were also used. These tissues were obtained at Tohoku University Hospital with informed consent and were reviewed by a board-approved pathologist. The protocol was approved by the Ethical Board of Tohoku University Hospital.
Northern blotting
Extracted total RNA (10 mg) was subjected to electrophoresis on a 1% agarose gel containing 5% formalin and then transferred to a Hybond N þ membrane (Amersham, Sweden). 6 We also used human MTN blot membranes containing 16 tissues (Clontech). Probes for ETS-1 and b-actin were obtained from RT-PCR products. Direct sequencing using ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction kit and a 310 DNA sequencer (Applied Biosystems, Foster City, CA) confirmed the sequences of these fragments. Digital autoradiography and quantification of the results were carried out using the BAS 1500 and Image Gauge 3.3 (Fujifilm, Japan) software.
Immunoblotting analysis
Western blotting was performed using 15-20 mg of total lysate as previously described. 28 Conditioned media were obtained, stored, and analyzed as previously described. 29 Primary antibodies used were: polyclonal rabbit antihuman ETS-1, goat anti-human MMP2 and MMP9 (Santa Cruz Laboratories, Santa Cruz, CA), monoclonal mouse anti-human b-actin (Sigma, St Louis, MO) antiHis6, and rabbit anti-human VEGF (Sigma). Secondary antibodies employed were: swine anti-rabbit, swine -antigoat (Tago Inc., Burlingame, CA) and a sheep anti-mouse peroxidase-conjugated antibody (Amersham, Buckinghamshire, UK). A total lysate of HPDEC-6 was used as a positive control. Immunoreactivity was subsequently demonstrated using the enhanced chemiluminescence ECL western blotting kit (Amersham). The relative intensity of signals was analyzed using the Luminescent Image Analyzer LAS-1000 Plus and Image software Gauge 3.3 (FUJI Photo Film, Co. Ltd, Kanagawa, Japan).
DNA-binding activity, dual luciferase assay and electrophoretic mobility shift assay DNA-binding assays for ETS-1 proteins were performed with 10 mg of nuclear extract, as described previously. 30 Competition assays were performed with a hundred-fold excess of unlabeled wild-type (WT) or mutant SBE (MT) oligonucleotides. For supershift assays, the nuclear extracts were incubated with 2 ml of ETS-1 antibodies for 30 min at room temperature before the addition of a labeled probe. Reactions were analyzed on a native 4% polyacrylamide gel and exposed to an imaging plate, which was then analyzed with a BAS 2000 image analyzer (Fuji, Tokyo, Japan).
Transfections and luciferase assays
Luciferase assays were conducted as described previously. 31 Briefly, the reporter construct was generated by inserting five head-to-tail ligated copies of the oligo 5 0 -TCGAGCAGGAAGTTTCG-3 0 , which contained the PEA3 ETS-binding site from the polyoma virus enhancer, into the pGL3-basic vector, which encoded firefly luciferase (FLS; Promega, Madison, WI). The cells were infected with AdETS-1, AdETS-1-DN or AdLacZ for 36 h at an MOI of 50. Each cell line was then seeded at 0.5 Â 10 5 cells per 10-mm dish and incubated overnight at 37 1C in an incubator containing 5% CO 2 . For each transfection, 0.1-0.3 mg of empty vector (pcDNA3; Invitrogen, Carlsbad, CA) and/or pRL-TK (Promega), along with 0.5-1 mg of promoter-luciferase DNA, were mixed together in 50 ml of Opti-MEM (Life Technologies Inc.), and a precipitate formed using LipofectAMINE 2000 (Life Technologies Inc.), according to the manufacturer's recommendations. The empty vector, pcDNA3, was used as a control for normalizing to total plasmid DNA. Cells were washed with Opti-MEM, and complexes were applied to the cells. After 36 h, FLS and renilla luciferase (RLS) gene activities in extracts from triplicate samples were sequentially measured by using a Dual Luciferase Reporter Assay System (Promega), according to the manufacturer's protocol. Measurements were performed automatically in a Luminescencer (Lumat LB 9507, Berthold, Germany), and results were expressed as fold increase compared to control cells.
In vitro proliferation assays Anchorage-dependent proliferation was monitored by an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for 5 days, and a daily proliferation index was calculated for each parental and corresponding hybrid cell line using previously described methods. 32, 33 The conversion of MTT to formazan dye was spectrometrically measured for absorbance at 590 nm, using a multi-well plate ImmunoReader System. All experiments were performed in duplicate sets of eight and repeated at least twice. Anchorage-independent proliferation (colony formation assay) was assessed in triplicate by two independent experiments as previously described. 31 The viable colonies were photographed using a Zeiss microscope with Â 5 objective. Both colony number and size were measured and averaged using three randomly chosen photographs from each plate, employing NIH 1.62 software. Data were pooled, averaged and then statistically analyzed.
In vivo proliferation assays Tissue sections of 5 mm thickness were prepared from formalin-fixed paraffin-embedded specimens. Immunohistochemical reactions were performed using a mouse anti-proliferating cell nuclear antigen (anti-PCNA, clone PC10, Dako Corporation) and developed with a Zymed Immunomouse kit (San Francisco, CA), as described previously. 
Invasion assays
Invasion through Matrigel-reconstituted basement membrane was induced by seeding 5000 cells into the upper compartment of the invasion chamber (Becton Dickinson Labware, Franklin Lakes, NJ) using serum-free medium and allowing the cells to invade for 18 h. 29 The invading cells were stained and photographed ( Â 100 magnification). Cells were counted and averaged, and the data were expressed as the number of migrated cells per high-power field. All experiments were performed in triplicate.
In vivo gene therapy experiments Eight-week-old, male, severe-combined immunodeficient nude mice (Clea Japan Inc., Tokyo, Japan) were maintained under pathogen-free conditions and used in accordance with NIH guidelines. For these experiments, an animal model was employed in which transductions were carried out either ex vivo or in vivo. In the ex vivo transduction model, gene transfer in PCI-35 and Panc-1 cells was achieved using adenoviral vectors encoding for the gene ETS-1, ETS-1/DN, or LacZ for 36 h at an MOI ranging from 50 to 100. Logarithmically growing cells trypsinized from subconfluent monolayers were suspended in medium containing 25% Matrigel Growth Factor Reduced (Becton Dickinson Labware) at a density of 1 Â 10 7 cells per ml. For each inoculation, 3 Â 10 6 cells in 0.3 ml of suspension were injected s.c. into the hind flanks of five nude mice. 33 Data from independent experiments were pooled for statistical analysis. At week 8, when the control tumors reached approximately 2000 mm 3 , the mice were killed. For the in vivo transduction we used a preestablished xenograft model. Cells were implanted by s.c. injection of 3 Â 10 6 cells in 300 ml of culture medium containing 10% matrigel into the dorsal surface of the 15 mice. Tumors were allowed to develop for 5-7 days until a volume of approximately 100 mm 3 was reached, and then the mice were divided into three experimental groups. Each mouse received intratumoral (i.t.) inoculation with excipient only (phosphate-buffered saline), Ad/LacZ or Ad/ETS-1-DN (10 10 PFU in 50 ml excipient) using a 32-gauge needle. Every animal received five i.t. injections spaced at 5-day intervals. The tumor diameters were measured before each injection with the use of a caliper. Mice were weighted and observed biweekly for monitoring of detectable side effects. One week after treatment was completed, the mice were killed and the tumors were excised for tissue sections.
Immunohistochemical analysis
Tumor samples were fixed overnight in phospholysineparaformaldehyde, embedded in optimal cutting temperature compound (Sakura Finetechnical Co., Ltd., Tokyo, Japan) and stored at À80 1C. Tumor samples fixed in 10% formalin and then embedded in paraffin were also used. Tumors grown in nude mice as well as 29 primary human pancreatic tumors were immunostained using rabbit antihuman ETS-1 antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA) as previously described. 17 The degree of ETS-1 expression in the human samples was assessed according to a previously reported method. 17, 35 All sections were reviewed independently by pathologists blinded to all clinical and pathologic information (TF and
Immunohistochemical staining with an anti-PECAM-1 antibody (clone MEC13.3; Pharmingen, San Diego, CA) was performed as previously described. 36 Microvessel density was estimated by counting five non-overlapping areas of tumor infiltration (1 mm 2 area) and the data are presented as means of relative microvessel structures area (in pixels) ± s.d. The immunostaining of gelatinases (MMP-1 and MMP-2) was performed as previously described, 37 ,38 using goat anti-mouse antibodies (Santa Cruz Biotechnology Inc.).
Statistical analysis
A two-tailed Student's t-test was computed by GraphPad Prism 3.0 software (GraphPad Software Inc., San Diego, CA) and used to determine the statistical significance of measured differences. Statistical significance was judged based on P-values o0.05.
Results
Expression of ETS-1 in human pancreatic cancer tissues and cell lines
The status of ETS-1 expression was defined using three pancreatic cancer cell lines (BxPC3, Panc-1 and PCI-35), a normal pancreatic ductal cell line (HPDEC-6) and 29 different pancreatic cancer specimens from our tissue library. Endogenous ETS-1 was expressed in all the pancreatic cancer cells, based on mRNA (Figures 1a-c) or protein analysis (Figure 1d ). In addition, apparently higher ETS-1 levels were found in SMAD4-null cell lines (Figures 1a-c, lines 1-2 ), in accordance with our previous findings. 6 The ETS-1 protein levels in human tissue samples appeared to correlate with tumor histology as previously reported.
17 ETS-1 expression was barely detectable in normal pancreatic ductal tissue (Figure 1f) . However, whole RNA pancreatic extract (Figure 1e ) revealed a relatively abundant expression of ETS-1. This differential expression was confirmed in vitro using cultured pancreatic ductal cells (HPDEC-6, Figure 1a , line 4). Remarkably, ETS-1 expression appeared stronger in the islets as compared with either normal or pancreatic (Figure 1g) , and moderately differentiated adenocarcinoma ( Figure  1h ) expressed gradually higher levels of ETS-1. In contrast, poorly differentiated adenocarcinoma (six cases had grade 0 expression) expressed relatively low levels of ETS-1 (Figure 1i ), suggesting that ETS-1 may play a more important role in the early stages of pancreatic tumorigenesis.
Pancreatic cancer cells expressing ETS-1-DN
Suppression of the ETS-1-binding activity was performed using an adenoviral vector encoding the His-6-tagged EBD but lacking the transactivation domain and most of automodulation module (AdETS-1-DN). The expression of exogenous ETS-1-DN RNA was first confirmed by northern blotting, demonstrating expression in transfected cells but not in noninfected or control virus-infected cells. Endogenous ETS-1 RNA was also detected in all parental and infected cells. The RNA levels of ETS-1-DN in PCI-35/ETS-1-DN and Panc-1/ETS-1-DN were significantly higher than those of endogenous ETS-1 (approximately 7-to 8-fold; Figure 2a) . To examine the DNA-binding activity of the ectopically expressed ETS-1-DN protein, we performed electrophoretic mobility assays using a 32 P-labeled double-stranded ETS-1 probe, as previously described. 30 ETS-1-specific DNA-binding activities were detected to a similar extent in both WT and control cells (Figure 2b, lanes 2  and 8) . Furthermore, ETS-1 specific DNA-binding activities appeared markedly reduced in the ETS-1-DN-infected cells (lane 4) when compared with those of parental or control infected cells (lanes 2 and 8) . The cold competition experiments showed that the ETS-1/ DNA-binding activity was specific (lanes 6), and supershift assays showed that the DNA-binding consisted of ETS-1 (lanes 3, 5 and 9). Moreover, a mutant 32 Plabeled ETS-1 probe failed to exhibit any binding activity (lane 7).
The ETS-1 transactivation activity was further analyzed using a luciferase construct containing an ETS-1-responsive promoter region. As shown in Figure 2c , ETS-1-DN significantly inhibited the transactivation activity of the construct. Taken together, these data show that suppression of functional activity of ETS-1 can be ETS-1-DN reduces the vascular density and growth of pancreatic cancer xenografts but has no anti-tumor effect in vitro Adenoviral-mediated transfer of ETS-1-DN (using AdETS-1-DN) in pancreatic tumor cell lines did not significantly affect their proliferation or degree of apoptosis in vitro (Table 1) . Nevertheless, AdETS-1-DN-infected cells exhibited a significant decrease in their invasiveness through the matrigel-reconstituted basement membrane, as compared with parental control cells (Table 1) . In contrast to the in vitro effect, ETS-1 downregulation significantly inhibited the in vivo tumor growth in nude mice injected with PCI-35 cells transduced with adenoviral vectors encoding ETS-1-DN, or LacZ (Figure 3a) .
In an attempt to test the efficacy of ETS-1-DN as an in vivo gene therapy agent, we directly delivered the AdETS-1-DN into preestablished human pancreatic adenocarcinomas grown in nude mice. After the fifth injection, there was a nearly 70% reduction of tumor size in the AdETS-1-DN-treated group, as compared with the saline-injected control group (Po0.05), without detectable side effects (Figures 3b-d) .
Microvessel density in mouse xenografts demonstrated significantly lower values in tumors with downregulated ETS-1 (Figures 4a and b) . A 48% reduction (P ¼ 0.026) in microvessel density was seen in ETS-1-DN-treated tumors as compared with control cells. The expression of PCNA, a nuclear marker of cell proliferation, showed no significant difference between treated and control tumors (Table 1) .
Transcriptional changes in pancreatic cancer cells upon ETS-1 blockade
The autocrine effect of ETS-1-DN in cancer cells was investigated by testing the changes in transcription of a panel of 10 known targets of ETS-1, such as VEGF, basic fibroblast growth factor (bFGF; data not shown), and proteases. Among these, expression of MMP-1 and u-PA were significantly downregulated by transcriptional suppression of ETS-1 (Figures 5a and b) . This suggests that transcriptional inhibition of ETS-1 elicits antiangiogenic effects through dysregulation of proteolytic factor gene expression downstream of ETS-1 signaling.
Discussion ETS transcription factors regulate many genes associated with tumor invasion, angiogenesis, cell adhesion, and organ development. The ETS family is comprised of more than 30 members that share a highly conserved DNAbinding motif termed the ETS domain. 39 In endothelial cells, the ETS-1-DNA-binding site has been reported to be included within the functional promoter site of many genes, including those encoding ECM-degrading enzymes like u-PA, MMP-1, MMP-3, MMP-9 and their inhibitors. Among them, the expression of several MMPs as well as u-PA was correlated with the progression of various cancers. 40, 41 Abbreviation: PCNA, proliferating cell nuclear antigen. a The colony number and size were measured and averaged from three randomly chosen photographs of each plate, using NIH 1.62 software. Apoptotic cells were detected by Annexin V/EGFP staining. Data were quantified using a FACScan and analyzed using the CellQuest software.
b The invading cells were counted, averaged, and compared to the control cells. Upregulation of ETS-1 expression has been documented in many types of human tumors. Generally, expression levels of ETS-1 correlate well with the grade of invasiveness and metastasis 42, 43 and can therefore be useful for predicting the prognosis of cancer patients. It has been reported that expression of ETS-1 is correlated with the progression of carcinoma cells of the stomach, 15 thyroid, 16 and pancreas. 17 ETS-1 possesses a typical oncogene profile as judged by the correlation of its overexpression with the histological stages of many cancers, including glioma 20 and pancreatic cancer.
17
Although ETS-1 is strongly expressed in the moderately and well-differentiated pancreatic lesions, our data reveal that its levels were lower in poorly differentiated pancreatic cancers, suggesting that ETS-1 is inactivated by an unknown mechanism in these lesions. However, the latter quality was established by examining tumors derived from pancreatic cancer cell lines. Specifically, BxPC-3 produces moderately well-differentiated adenocarcinomas, 44 whereas Panc-1 maintains a poorly differentiated phenotype. 45 Furthermore, in an orthotopic pancreatic cancer model, marked differences with regard to tumor size, metastatic spread, and survival were found, depending on the grade of differentiation. Namely, less differentiated cells (Panc-1) caused higher dissemination scores and mortality than cells displaying greater differentiation. However, it is conceivable that the development of efficacious therapeutic treatments for human cancers relies significantly upon the presence and activity of the primary oncogene target. 46 In our study, the tumoral regression observed with local administration of Ad/ETS-1-DN appears to be significantly higher when the ETS-1 is abundantly expressed (Figure 1) . However, IHC revealed that ETS-1 appears to be expressed more strongly in islets than in normal pancreatic ductal tissue or HPDEC-6 cells. To our knowledge, the significance, if any, of ETS-1 expression in the pancreatic islets is not known, and further focused studies may elucidate this phenomenon.
Expression of genes encoding for enzymes involved in degradation of the ECM, such as MMP-1, MMP-3, MMP-7 and MMP-9, is regulated by ETS family proteins such as ETS-1. Hence, it is highly suggestive that ETS-1 contributes to tumor invasion and progression through activation of these enzymes. Indeed, expression of these ECM remodeling enzymes is often detected along with c-ETS-1 mRNA in tumor cells, a phenomenon that correlates with poor survival in human ovarian carcinoma. 47 Moreover, ETS-1 is upregulated in human hepatocellular carcinoma (HCC), where it enhances expression of MMP-7, thus potentially contributing to the progres- , the mice were killed (a). For the in vivo transduction therapy experiments, tumors were generated by s.c. injection of 3 Â 10 6 cells in 300 ml of culture medium containing 10% Matrigel into the dorsal surface of mice (b-d). Tumors were allowed to develop for 5-7 days to about 100 mm 3 volume, and then mice were divided into three experimental groups. Each mouse received intratumoral (i.t.) inoculation with either excipient only (phosphate-buffered saline), Ad/LacZ, or Ad/ETS-1-DN (10 10 PFU in 50 ml excipient). Each animal received five i.t. injections spaced at 5-day intervals. The tumor diameters were measured using a caliper before each administration. Data from independent experiments were pooled for statistical analysis.
Targeting ETS-1 for antiangiogenesis LP Lefter et al sion of HCC. 48 Although many potential target genes for the ETS family proteins have been identified, most studies have been carried out with the use of in vitro assays exclusively. Several studies used a truncated molecule containing EBD to downregulate ETS activity in capillary endothelial or glioma cells. 19, 20 Hence, ETS-1 positively regulates angiogenesis, and using a dominant-negative molecule to eliminate ETS-1 activity resulted in angiogenesis inhibition in vivo. Consequently, we hypothesized that ETS-1 may be a useful target for gene therapy to combat the progression of pancreatic adenocarcinomas.
In this study, we have shown that ETS-1 is an effective target for gene therapy in pancreatic cancer using an animal model in which transductions were carried out either ex vivo or in vivo. We have investigated the effect of an ETS-1-DN molecule in a panel of three pancreatic cancer cells using ex vivo and in vivo gene therapy models. Adenoviral-mediated transfer of ETS-1-DN in pancreatic tumor cell lines did not affect their proliferation rate in vitro, but significantly delayed their in vivo growth in both nude mouse xenograft models used in this study. Our data clearly indicate that the ETS-1-DN molecule acted in a dominant-negative manner against ETS-1 by competing for its DNA-binding activity. In our system, the inhibition of the endogenous ETS-1 could not be completely abolished, results similar to those reported by Nakano et al. 19 using stable ETS-1-DN stable transfectants. This could be because of the use of transient transfections or to an autocrine loop that is able to restore ETS-1-binding activity. ETS-1 is also involved in angiogenesis, which is Figure 4 Representative data from immunohistochemical analysis of pancreatic cancer xenografts. Cells were infected as described in Materials and methods section and then inoculated s.c. in nude mice. At day 30, mice were killed and their tumors excised. Sections were stained with polyclonal rabbit anti-erythroblastosis virus E26 oncogene homolog 1 (ETS-1) antibody. A significant decrease of ETS-1 immunoreactivity was observed in ETS-1 dominant negative (ETS-1-DN) as compared with wild-type and ETS-1 tumors (a). Microvessel density was estimated using PECAM-1 reactivity. A 48% reduction in microvessel density was seen in ETS-1-DN-treated tumors as compared with control cells (b). Original magnifications are indicated on borders and the squares show the subsequently magnified area.
essential for tumor progression. In fact, induction of ETS-1 expression appears to be a common phenomenon in endothelial cells following stimulation by angiogenic growth factors. 30 Angiogenesis is a necessary and required step for the transition from a small harmless cluster of cells to a large tumor, as well as for independent metastases. 49 We achieved a significant suppression of the tumor-induced angiogenesis by curtailing ETS-1-binding activity. It has been shown that VEGF and bFGF induce ETS-1 in endothelial cells, and ETS-1 then confers an angiogenic phenotype to endothelial cells through induction of u-PA and MMPs. In support of previous studies, our findings clearly indicate that the ETS-1-DN antiangiogenic effect is partly mediated through downregulation of MMP-1 and u-PA, both known downstream targets of ETS-1. Intriguingly, the expression levels of angiogenic factors such as VEGF, bFGF, MMP-2 and MMP-9, all well-known ETS-1 targets, were found to be unchanged by the experimental suppression of ETS-1 activity (data not shown). Nonetheless, such discrepancies appear to be based on differences in cellular make-up, which may include interactions between positive and negative regulators specific to different cell types. 50 For example, ETS-1 induces Fli-1 in endothelial cells but not in fibroblasts. 51 Although demonstrating the efficiency of ETS-1-DN as an antiangiogenic agent, this study raises important questions regarding the deregulated targets downstream of ETS-1. Here, we demonstrated that downregulation of MMP-1 and u-PA occurs after transcriptional repression of ETS-1. It is conceivable that other known or unknown targets could be affected by the ETS-1 signaling cascade, and further mechanistic studies are warranted. However, the relevance of these future studies will depend upon the recognition of all the facets of the physiological roles of these transcription factors. Moreover, because the binding of ETS-1 to various ETS targets in certain tissues depends on the particular cellular context, future studies should identify the in vivo targets, including known or novel genes, in specific cell lineages. To this end, we are employing microarrays designed to reveal new targets downstream of ETS-1 signaling in pancreatic cancer.
Taken together, these results suggest that eliminating the ETS-1-binding activity efficiently suppresses the angiogenic and invasive abilities of pancreatic cancer cells. Moreover, this study indicates that ETS-1 should be considered a potential anticancer target for in vivo gene therapy in pancreatic cancer.
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